Navigation Links
Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc.
Date:4/2/2009

COPENHAGEN, April 2 /PRNewswire/ -- Nuevolution A/S today announced that Merck & Co. Inc. has chosen to proceed to the second phase of the collaboration agreement announced in June 2008 to apply Nuevolution's proprietary Chemetics(R) drug discovery technology to identify novel small molecule leads against several drug targets.

By entering the second phase, Merck gains access to a new multi-million member proprietary library of small molecule drug candidates. In addition, this development triggers the payment of an undisclosed technology access fee to Nuevolution from Merck.

"We are pleased with Merck's decision to proceed with the collaboration into its second phase," said Alex Gouliaev, CEO of Nuevolution A/S. "We look forward to decoding the active structures arising from this proprietary library."

About Nuevolution

Nuevolution is a leading drug discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics(R), a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics(R) enables rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing drug discovery technologies.

Nuevolution partners its technology with pharmaceutical and biotechnology companies, and is also developing an internal pipeline by applying Chemetics(R) to validated cancer and cardiovascular targets. Nuevolution has demonstrated the power of Chemetics(R) by identifying highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes.

Nuevolution is a privately owned company and has raised euro 37 million in financing from key Scandinavian investors, including SEB Venture, Sunstone Capital, SLS Venture and Novo A/S. For more information about Nuevolution A/S, please visit the company's website www.nuevolution.com

    For further information please contact:

    Nuevolution A/S
    Alex Haahr Gouliaev, CEO
    Phone: +45 7020 0987
    ahg@nuevolution.com


'/>"/>
SOURCE Nuevolution A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
2. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
3. China Biologic Products Announces Strong 2008 Results
4. Senetek PLC Announces New Investor Communication Hotline
5. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
6. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
7. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
8. ArunA Biomedical Announces Co-development of Fully Validated Induced Pluripotent Stem Cell Kit
9. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
10. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
11. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):